Bode Cellmark Forensics Enters into Service Agreement in Support of Innovative Programs Dedicated to Processing Sexual Assau...
September 30 2015 - 08:45AM
Business Wire
Laboratory Corporation of America® Holdings (LabCorp®) (NYSE:
LH) announced today that Bode Cellmark Forensics, a member of the
LabCorp Specialty Testing Group, has entered into an agreement with
the New York County District Attorney’s Office (DANY) that
recognizes Bode Cellmark as a preferred forensic laboratory
eligible to process untested sexual assault kits for grant
recipients of DANY’s Sexual Assault Kit Backlog Elimination
Program. Grant recipients are now able to contract directly with
Bode Cellmark for forensic DNA testing services. In addition, Bode
Cellmark is eligible to perform testing for the U.S. Department of
Justice’s Bureau of Justice Assistance (BJA) Sexual Assault Kit
Initiative, which recently awarded additional grants to address the
nation’s sexual assault kit backlog.
These programs will provide grants of approximately $79 million
to qualified police departments and crime labs throughout the
United States, enabling these law enforcement agencies to pay for
forensic DNA testing services and to promote policies and
procedures designed to improve the handling of sexual assault
cases. Failure to test sexual assault kits, which contain evidence
that may be used to identify and prosecute perpetrators of sexual
assault, contributes to a national sexual assault arrest rate of
less than 25%. Agencies that have developed policies to test every
sexual assault kit have seen arrest rates increase, as evidenced in
New York where arrests for sexual assault jumped from 40% to
70%1.
“As the largest provider of forensic DNA analysis services in
the United States, Bode Cellmark is pleased to offer high-quality,
cost-effective testing to reduce the backlog of sexual assault
kits,” said Michael Cariola, General Manager of Bode Cellmark. “We
look forward to utilizing more than three decades of casework
experience, including past support of innovative programs in New
York, Detroit and other cities, to provide forensic DNA testing
solutions for DANY and BJA grant recipients.”
All DNA analysis methods performed by Bode Cellmark utilize
validated procedures that meet the FBI’s Quality Assurance
Standards and ISO/IEC 17025 accreditation requirements.
About LabCorp®
Laboratory Corporation of America® Holdings, an S&P 500
company, is the world’s leading healthcare diagnostics company,
providing comprehensive clinical laboratory services through
LabCorp Diagnostics, and end-to-end drug development support
through Covance Drug Development. LabCorp is a pioneer in
commercializing new diagnostic technologies and is improving
people’s health by delivering the combination of world-class
diagnostics, drug development and knowledge services. With combined
revenue pro forma for the acquisition of Covance in excess of $8.5
billion in 2014 and more than 48,000 employees in over 60
countries, LabCorp offers innovative solutions to healthcare
stakeholders. LabCorp clients include physicians, patients and
consumers, biopharmaceutical companies, government agencies,
managed care organizations, hospitals, and clinical labs. To learn
more about Covance Drug Development, visit www.covance.com. To
learn more about LabCorp and LabCorp Diagnostics, visit
www.labcorp.com.
This press release contains forward-looking statements including
with respect to estimated 2015 guidance and the impact of various
factors on operating results. Each of the forward-looking
statements is subject to change based on various important factors,
including without limitation, competitive actions in the
marketplace, adverse actions of governmental and other third-party
payers and the results from the Company’s acquisition of Covance.
Actual results could differ materially from those suggested by
these forward-looking statements. Further information on potential
factors that could affect LabCorp’s operating and financial results
is included in the Company’s Form 10-K for the year ended December
31, 2014, and the Company’s Form 10-Q for the quarter ended June
30, 2015, including in each case under the heading risk factors,
and in the Company’s other filings with the SEC, as well as in the
risk factors included in Covance’s filings with the SEC. The
information in this press release should be read in conjunction
with a review of the Company’s filings with the SEC including the
information in the Company’s Form 10-K for the year ended December
31, 2014, and subsequent Forms 10-Q, under the heading MANAGEMENT’S
DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF
OPERATIONS.
1 Source: http://www.endthebacklog.org/backlog/what-backlog
View source
version on businesswire.com: http://www.businesswire.com/news/home/20150930005928/en/
Laboratory Corporation of America® HoldingsInvestor/Media
Contact:Paul Surdez, 336-436-5076Company Information:
www.labcorp.com
Laboratory Corporation o... (NYSE:LH)
Historical Stock Chart
From Feb 2024 to Mar 2024
Laboratory Corporation o... (NYSE:LH)
Historical Stock Chart
From Mar 2023 to Mar 2024